Graves’ Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Graves’ Disease Market Outlook
Thelansis’s “Graves’ Disease Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Graves’ Disease treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Graves’
Disease Overview
Graves’
Disease, an autoimmune disorder, leads to hyperthyroidism, an excessive
production of thyroid hormones. The condition arises when the body’s immune
system mistakenly attacks the thyroid gland, prompting it to generate more
thyroid hormone than necessary. Situated in the neck, the thyroid, resembling a
small butterfly, regulates energy usage throughout the body, influencing the
function of almost every organ, including heart rate. Left untreated,
hyperthyroidism can result in severe complications affecting the heart, bones,
muscles, menstrual cycle, and fertility. During pregnancy, untreated
hyperthyroidism poses risks for both mother and baby. Additionally, Graves’
Disease can manifest symptoms in the eyes and skin. Individuals with other
autoimmune disorders face a higher likelihood of developing Graves’ Disease.
Conditions such as rheumatoid arthritis, affecting joints and potentially other
bodily systems; pernicious anemia, stemming from a vitamin B12 deficiency;
lupus, a chronic multi-system disorder; and Addison’s Disease, a hormonal
imbalance, are commonly associated with Graves’ Disease. Moreover, digestive
disorder celiac disease, skin depigmentation condition vitiligo, and type 1
diabetes are among the potential links.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment